Evidence map›Paper›PMID 39350044›Full record

ArticleBMC cancer2024

Mutational signatures in 175 Chinese gastric cancer patients.

Fatao Liu, Nan Hu, Kewei Jiang, Huaitian Liu, Mingyi Wang, Ying Hu, Tongwu Zhang, Ho-Hsiang Wu, Howard Yang, Hao Weng and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fatao LiuShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, P. R. China.
Nan HuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Kewei JiangDepartment of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, 100044, P. R. China.
Huaitian LiuCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Mingyi WangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Ying HuCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Tongwu ZhangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Ho-Hsiang WuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Howard YangCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Hao WengShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, P. R. China.
Ping DongShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, P. R. China.
Carol GiffenInformation Management Services, Inc, Silver Spring, Bethesda, MD, 20904, USA.
Bin ZhuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Maxwell P LeeCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Christian C AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Philip R TaylorDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Yun LiuDepartment of Oncology, Fudan University Pudong Medical Center, Shanghai, P. R. China. superliuyun@fudan.edu.cn.
Yingbin LiuShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, P. R. China. liuyingbin@xinhuamed.com.cn.
Alisa M GoldsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA. goldstea@mail.nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC), a molecularly heterogeneous disease, is the third leading cause of cancer death worldwide. The majority of GC cases worldwide occur in East Asia, predominantly China. Mutational Signature Framework offers an elegant approach to identify mutational processes present in tumors.

methodsTo identify mutational signature patterns, we conducted whole exome sequencing (WES) analysis in Chinese patients with GC. Mutect2 and MutsigCV were used to identify significantly mutated genes in 175 Chinese GC cases using paired tumor-normal tissues. We investigated mutational signatures using Catalogue of Somatic Mutations in Cancer (COSMIC) Version 2 (V2) and Version 3 (V3).

resultsWe identified 104 mutated genes with P < 0.01. Seven genes (OR6B1, B2M, ELF3, RHOA, RPL22, TP53, ARIDIA) had q < 0.0001, including six previously associated with GC. Mutational signatures (COSMIC-V3) observed include 14 single base substitutions (SBS), one doublet base substitution (DBS) Signature A, and one InDel (ID2). The most frequent SBS signatures (SBS05, SBS01, SBS15, SBS20, SBS40) were also observed in 254 White GC cases from The Cancer Genome Atlas (TCGA) Project. However, SBS01 and SBS20 showed significant differences between Whites vs. All Asians (19.3% vs. 11.3% for SBS 1 (P = 0.012) and 11.4% vs. 5.9% for SBS20 (P = 0.025), respectively). Using COSMIC V2, signatures 6, 15, and 1 were the most frequent in Chinese GC cases. Further, most Chinese GC cases carried multiple signatures.

conclusionsThis effort represents the most detailed mutational signatures analysis of GC cases from China to date. Results hold promise for new insights in understanding risk and prognosis factors in GC.

Indexed as

East Asian PeopleExome SequencingStomach NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorChinaDNA Mutational AnalysisFemaleHumansMaleMiddle AgedMutationBiomarkers, TumorDriver genesGastric cancerMutational signaturesSomatic alterationsTumor molecular heterogeneity

Identifiers

PMID39350044
PMCPMC11440915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.